SCHEMBL30590804

SCHEMBL30590804

O=c1[nH]cnc2cc(Cl)c(Cl)nc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 11/20 0.45
ALDH1A1 P00352 1/20 0.45
PIM1 P11309 4/20 0.41
RPS6KA3 P51812 2/20 0.41
AURKA O14965 2/20 0.41
DAPK3 O43293 2/20 0.41
PRKD3 O94806 2/20 0.41
MAP4K4 O95819 2/20 0.41
RET P07949 2/20 0.41
IGF1R P08069 2/20 0.41
CLK2 P49760 2/20 0.41
GSK3A P49840 2/20 0.41
GSK3B P49841 2/20 0.41
PRKX P51817 2/20 0.41
BTK Q06187 2/20 0.41
TYRO3 Q06418 2/20 0.41
DYRK1A Q13627 2/20 0.41
NTRK3 Q16288 2/20 0.41
TAOK1 Q7L7X3 2/20 0.41
CLK4 Q9HAZ1 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26112788 1.00 PARP1 (0.45) PARP1ALDH1A1PIM1RPS6KA3AURKA
SCHEMBL26112587 0.79 SRC (0.52) PARP1ALDH1A1PIM1RPS6KA3ALK
SCHEMBL30590825 0.79 SRC (0.52) PARP1ALDH1A1PIM1RPS6KA3ALK
SCHEMBL31352773 0.77 SRC (0.38) PARP1ALDH1A1PIM1RPS6KA3PDPK1
SCHEMBL26112062 0.77 SRC (0.38) PARP1ALDH1A1PIM1RPS6KA3PDPK1
SCHEMBL26112568 0.75 PARP1 (0.36) PARP1ALDH1A1JAK2MAP2K1PDPK1
SCHEMBL30590827 0.75 PARP1 (0.36) PARP1ALDH1A1JAK2MAP2K1PDPK1
SCHEMBL25432823 0.73 KDM4E (0.43) PARP1ALDH1A1PIM1RPS6KA3AURKA
SCHEMBL3922866 0.73 ALDH1A1 (0.54) PARP1ALDH1A1PIM1RPS6KA3AURKA
SCHEMBL669572 0.73 PARP1 (0.50) PARP1ALDH1A1PIM1RPS6KA3AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250236608-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-07-24 US disclosed
EP-4504719-A1 EGFR INHIBITORS Blueprint Medicines Corporation (US) 2025-02-12 EP disclosed
CN-119325471-A EGFR inhibitors 缆图药品公司 2025-01-17 CN disclosed
WO-2023196283-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2023-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250236608-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 PARP1 2538/4885ALDH1A1 2147/4885PIM1 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.